id	sid	tid	token	lemma	pos
work_kwvyudrv4zalznxpzztokxrdee	1	1	PHP24	PHP24	NNP
work_kwvyudrv4zalznxpzztokxrdee	1	2	A	a	DT
work_kwvyudrv4zalznxpzztokxrdee	1	3	SYSTEMATIC	systematic	JJ
work_kwvyudrv4zalznxpzztokxrdee	1	4	REVIEW	REVIEW	NNP
work_kwvyudrv4zalznxpzztokxrdee	1	5	OF	of	IN
work_kwvyudrv4zalznxpzztokxrdee	1	6	THE	the	DT
work_kwvyudrv4zalznxpzztokxrdee	1	7	EUROPEAN	EUROPEAN	NNP
work_kwvyudrv4zalznxpzztokxrdee	1	8	PHARMACEUTICAL	PHARMACEUTICAL	NNP
work_kwvyudrv4zalznxpzztokxrdee	1	9	MARKET	MARKET	NNP
work_kwvyudrv4zalznxpzztokxrdee	1	10	AND	and	CC
work_kwvyudrv4zalznxpzztokxrdee	1	11	THE	the	DT
work_kwvyudrv4zalznxpzztokxrdee	1	12	IMPACT	IMPACT	NNP
work_kwvyudrv4zalznxpzztokxrdee	1	13	OF	of	IN
work_kwvyudrv4zalznxpzztokxrdee	1	14	EUROPEAN	EUROPEAN	NNP
work_kwvyudrv4zalznxpzztokxrdee	1	15	UNION	UNION	NNP
work_kwvyudrv4zalznxpzztokxrdee	1	16	REGULATION	REGULATION	NNP
work_kwvyudrv4zalznxpzztokxrdee	1	17	AND	and	CC
work_kwvyudrv4zalznxpzztokxrdee	1	18	JURISDICTION	jurisdiction	NN
work_kwvyudrv4zalznxpzztokxrdee	1	19	A188	A188	NNP
work_kwvyudrv4zalznxpzztokxrdee	1	20	Abstracts	abstract	VBZ
work_kwvyudrv4zalznxpzztokxrdee	1	21	PHP23	PHP23	NNP
work_kwvyudrv4zalznxpzztokxrdee	1	22	A	a	DT
work_kwvyudrv4zalznxpzztokxrdee	1	23	COMPARATIVE	comparative	JJ
work_kwvyudrv4zalznxpzztokxrdee	1	24	ANALYSIS	analysis	NN
work_kwvyudrv4zalznxpzztokxrdee	1	25	OF	of	IN
work_kwvyudrv4zalznxpzztokxrdee	1	26	THE	the	DT
work_kwvyudrv4zalznxpzztokxrdee	1	27	FINANCING	financing	NN
work_kwvyudrv4zalznxpzztokxrdee	1	28	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	1	29	PRICING	pricing	NN
work_kwvyudrv4zalznxpzztokxrdee	1	30	AND	and	CC
work_kwvyudrv4zalznxpzztokxrdee	1	31	REIMBURSEMENT	reimbursement	NN
work_kwvyudrv4zalznxpzztokxrdee	1	32	SYSTEMS	system	NNS
work_kwvyudrv4zalznxpzztokxrdee	1	33	FOR	for	IN
work_kwvyudrv4zalznxpzztokxrdee	1	34	PRESCRIPTION	prescription	NN
work_kwvyudrv4zalznxpzztokxrdee	1	35	DRUGS	drug	NNS
work_kwvyudrv4zalznxpzztokxrdee	1	36	IN	in	IN
work_kwvyudrv4zalznxpzztokxrdee	1	37	THE	the	DT
work_kwvyudrv4zalznxpzztokxrdee	1	38	NORDIC	nordic	JJ
work_kwvyudrv4zalznxpzztokxrdee	1	39	COUNTRIES	country	NNS
work_kwvyudrv4zalznxpzztokxrdee	1	40	Kristensen	Kristensen	NNP
work_kwvyudrv4zalznxpzztokxrdee	1	41	FKO	FKO	NNP
work_kwvyudrv4zalznxpzztokxrdee	1	42	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	1	43	Sverre	Sverre	NNP
work_kwvyudrv4zalznxpzztokxrdee	1	44	JM	JM	NNP
work_kwvyudrv4zalznxpzztokxrdee	1	45	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	1	46	Holm	Holm	NNP
work_kwvyudrv4zalznxpzztokxrdee	1	47	LB	LB	NNP
work_kwvyudrv4zalznxpzztokxrdee	1	48	PharmEcon	PharmEcon	NNP
work_kwvyudrv4zalznxpzztokxrdee	1	49	AS	AS	NNP
work_kwvyudrv4zalznxpzztokxrdee	1	50	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	1	51	Asker	Asker	NNP
work_kwvyudrv4zalznxpzztokxrdee	1	52	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	1	53	Norway	Norway	NNP
work_kwvyudrv4zalznxpzztokxrdee	1	54	OBJECTIVES	OBJECTIVES	NNP
work_kwvyudrv4zalznxpzztokxrdee	1	55	:	:	:
work_kwvyudrv4zalznxpzztokxrdee	1	56	To	to	TO
work_kwvyudrv4zalznxpzztokxrdee	1	57	elicit	elicit	JJ
work_kwvyudrv4zalznxpzztokxrdee	1	58	similarities	similarity	NNS
work_kwvyudrv4zalznxpzztokxrdee	1	59	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	1	60	differences	difference	NNS
work_kwvyudrv4zalznxpzztokxrdee	1	61	in	in	IN
work_kwvyudrv4zalznxpzztokxrdee	1	62	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	1	63	poli-	poli-	JJ
work_kwvyudrv4zalznxpzztokxrdee	1	64	cies	cie	NNS
work_kwvyudrv4zalznxpzztokxrdee	1	65	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	1	66	practices	practice	NNS
work_kwvyudrv4zalznxpzztokxrdee	1	67	for	for	IN
work_kwvyudrv4zalznxpzztokxrdee	1	68	financing	financing	NN
work_kwvyudrv4zalznxpzztokxrdee	1	69	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	1	70	pricing	pricing	NN
work_kwvyudrv4zalznxpzztokxrdee	1	71	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	1	72	reimbursing	reimburse	VBG
work_kwvyudrv4zalznxpzztokxrdee	1	73	pre-	pre-	NN
work_kwvyudrv4zalznxpzztokxrdee	1	74	scription	scription	NN
work_kwvyudrv4zalznxpzztokxrdee	1	75	drugs	drug	NNS
work_kwvyudrv4zalznxpzztokxrdee	1	76	in	in	IN
work_kwvyudrv4zalznxpzztokxrdee	1	77	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	1	78	often	often	RB
work_kwvyudrv4zalznxpzztokxrdee	1	79	perceived	perceive	VBN
work_kwvyudrv4zalznxpzztokxrdee	1	80	similar	similar	JJ
work_kwvyudrv4zalznxpzztokxrdee	1	81	Nordic	nordic	JJ
work_kwvyudrv4zalznxpzztokxrdee	1	82	countries	country	NNS
work_kwvyudrv4zalznxpzztokxrdee	1	83	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	1	84	Denmark	Denmark	NNP
work_kwvyudrv4zalznxpzztokxrdee	1	85	(	(	-LRB-
work_kwvyudrv4zalznxpzztokxrdee	1	86	D	D	NNP
work_kwvyudrv4zalznxpzztokxrdee	1	87	)	)	-RRB-
work_kwvyudrv4zalznxpzztokxrdee	1	88	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	1	89	Finland	Finland	NNP
work_kwvyudrv4zalznxpzztokxrdee	1	90	(	(	-LRB-
work_kwvyudrv4zalznxpzztokxrdee	1	91	F	F	NNP
work_kwvyudrv4zalznxpzztokxrdee	1	92	)	)	-RRB-
work_kwvyudrv4zalznxpzztokxrdee	1	93	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	1	94	Norway	Norway	NNP
work_kwvyudrv4zalznxpzztokxrdee	1	95	(	(	-LRB-
work_kwvyudrv4zalznxpzztokxrdee	1	96	N	N	NNP
work_kwvyudrv4zalznxpzztokxrdee	1	97	)	)	-RRB-
work_kwvyudrv4zalznxpzztokxrdee	1	98	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	1	99	Sweden	Sweden	NNP
work_kwvyudrv4zalznxpzztokxrdee	1	100	(	(	-LRB-
work_kwvyudrv4zalznxpzztokxrdee	1	101	S	S	NNP
work_kwvyudrv4zalznxpzztokxrdee	1	102	)	)	-RRB-
work_kwvyudrv4zalznxpzztokxrdee	1	103	.	.	.
work_kwvyudrv4zalznxpzztokxrdee	2	1	METHODS	METHODS	NNP
work_kwvyudrv4zalznxpzztokxrdee	2	2	:	:	:
work_kwvyudrv4zalznxpzztokxrdee	2	3	A	a	DT
work_kwvyudrv4zalznxpzztokxrdee	2	4	review	review	NN
work_kwvyudrv4zalznxpzztokxrdee	2	5	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	2	6	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	2	7	four	four	CD
work_kwvyudrv4zalznxpzztokxrdee	2	8	countries	country	NNS
work_kwvyudrv4zalznxpzztokxrdee	2	9	’	’	POS
work_kwvyudrv4zalznxpzztokxrdee	2	10	authorities	authority	NNS
work_kwvyudrv4zalznxpzztokxrdee	2	11	’	’	POS
work_kwvyudrv4zalznxpzztokxrdee	2	12	stated	state	VBN
work_kwvyudrv4zalznxpzztokxrdee	2	13	policies	policy	NNS
work_kwvyudrv4zalznxpzztokxrdee	2	14	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	2	15	practices	practice	NNS
work_kwvyudrv4zalznxpzztokxrdee	2	16	on	on	IN
work_kwvyudrv4zalznxpzztokxrdee	2	17	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	2	18	matter	matter	NN
work_kwvyudrv4zalznxpzztokxrdee	2	19	were	be	VBD
work_kwvyudrv4zalznxpzztokxrdee	2	20	performed	perform	VBN
work_kwvyudrv4zalznxpzztokxrdee	2	21	through	through	IN
work_kwvyudrv4zalznxpzztokxrdee	2	22	a	a	DT
work_kwvyudrv4zalznxpzztokxrdee	2	23	search	search	NN
work_kwvyudrv4zalznxpzztokxrdee	2	24	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	2	25	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	2	26	literature	literature	NN
work_kwvyudrv4zalznxpzztokxrdee	2	27	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	2	28	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	2	29	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	2	30	respective	respective	JJ
work_kwvyudrv4zalznxpzztokxrdee	2	31	authorities	authority	NNS
work_kwvyudrv4zalznxpzztokxrdee	2	32	’	’	POS
work_kwvyudrv4zalznxpzztokxrdee	2	33	home-	home-	NN
work_kwvyudrv4zalznxpzztokxrdee	2	34	pages	page	NNS
work_kwvyudrv4zalznxpzztokxrdee	2	35	.	.	.
work_kwvyudrv4zalznxpzztokxrdee	3	1	The	the	DT
work_kwvyudrv4zalznxpzztokxrdee	3	2	information	information	NN
work_kwvyudrv4zalznxpzztokxrdee	3	3	was	be	VBD
work_kwvyudrv4zalznxpzztokxrdee	3	4	validated	validate	VBN
work_kwvyudrv4zalznxpzztokxrdee	3	5	through	through	IN
work_kwvyudrv4zalznxpzztokxrdee	3	6	interviews	interview	NNS
work_kwvyudrv4zalznxpzztokxrdee	3	7	with	with	IN
work_kwvyudrv4zalznxpzztokxrdee	3	8	key	key	JJ
work_kwvyudrv4zalznxpzztokxrdee	3	9	personnel	personnel	NNS
work_kwvyudrv4zalznxpzztokxrdee	3	10	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	3	11	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	3	12	reimbursement	reimbursement	NN
work_kwvyudrv4zalznxpzztokxrdee	3	13	agencies	agency	NNS
work_kwvyudrv4zalznxpzztokxrdee	3	14	in	in	IN
work_kwvyudrv4zalznxpzztokxrdee	3	15	each	each	DT
work_kwvyudrv4zalznxpzztokxrdee	3	16	country	country	NN
work_kwvyudrv4zalznxpzztokxrdee	3	17	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	3	18	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	3	19	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	3	20	final	final	JJ
work_kwvyudrv4zalznxpzztokxrdee	3	21	study	study	NN
work_kwvyudrv4zalznxpzztokxrdee	3	22	reports	report	VBZ
work_kwvyudrv4zalznxpzztokxrdee	3	23	for	for	IN
work_kwvyudrv4zalznxpzztokxrdee	3	24	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	3	25	respective	respective	JJ
work_kwvyudrv4zalznxpzztokxrdee	3	26	countries	country	NNS
work_kwvyudrv4zalznxpzztokxrdee	3	27	were	be	VBD
work_kwvyudrv4zalznxpzztokxrdee	3	28	reviewed	review	VBN
work_kwvyudrv4zalznxpzztokxrdee	3	29	by	by	IN
work_kwvyudrv4zalznxpzztokxrdee	3	30	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	3	31	same	same	JJ
work_kwvyudrv4zalznxpzztokxrdee	3	32	persons	person	NNS
work_kwvyudrv4zalznxpzztokxrdee	3	33	.	.	.
work_kwvyudrv4zalznxpzztokxrdee	4	1	RESULTS	RESULTS	NNP
work_kwvyudrv4zalznxpzztokxrdee	4	2	:	:	:
work_kwvyudrv4zalznxpzztokxrdee	4	3	All	all	DT
work_kwvyudrv4zalznxpzztokxrdee	4	4	countries	country	NNS
work_kwvyudrv4zalznxpzztokxrdee	4	5	have	have	VBP
work_kwvyudrv4zalznxpzztokxrdee	4	6	a	a	DT
work_kwvyudrv4zalznxpzztokxrdee	4	7	national	national	JJ
work_kwvyudrv4zalznxpzztokxrdee	4	8	health	health	NN
work_kwvyudrv4zalznxpzztokxrdee	4	9	care	care	NN
work_kwvyudrv4zalznxpzztokxrdee	4	10	system	system	NN
work_kwvyudrv4zalznxpzztokxrdee	4	11	financed	finance	VBN
work_kwvyudrv4zalznxpzztokxrdee	4	12	by	by	IN
work_kwvyudrv4zalznxpzztokxrdee	4	13	taxation	taxation	NN
work_kwvyudrv4zalznxpzztokxrdee	4	14	.	.	.
work_kwvyudrv4zalznxpzztokxrdee	5	1	There	there	EX
work_kwvyudrv4zalznxpzztokxrdee	5	2	are	be	VBP
work_kwvyudrv4zalznxpzztokxrdee	5	3	dif-	dif-	RB
work_kwvyudrv4zalznxpzztokxrdee	5	4	ferences	ference	NNS
work_kwvyudrv4zalznxpzztokxrdee	5	5	in	in	IN
work_kwvyudrv4zalznxpzztokxrdee	5	6	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	5	7	reliance	reliance	NN
work_kwvyudrv4zalznxpzztokxrdee	5	8	upon	upon	IN
work_kwvyudrv4zalznxpzztokxrdee	5	9	patient	patient	JJ
work_kwvyudrv4zalznxpzztokxrdee	5	10	co	co	NN
work_kwvyudrv4zalznxpzztokxrdee	5	11	-	-	NN
work_kwvyudrv4zalznxpzztokxrdee	5	12	payment	payment	NN
work_kwvyudrv4zalznxpzztokxrdee	5	13	(	(	-LRB-
work_kwvyudrv4zalznxpzztokxrdee	5	14	N	n	CD
work_kwvyudrv4zalznxpzztokxrdee	5	15	13	13	CD
work_kwvyudrv4zalznxpzztokxrdee	5	16	%	%	NN
work_kwvyudrv4zalznxpzztokxrdee	5	17	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	5	18	others	other	NNS
work_kwvyudrv4zalznxpzztokxrdee	5	19	22–37	22–37	CD
work_kwvyudrv4zalznxpzztokxrdee	5	20	%	%	NN
work_kwvyudrv4zalznxpzztokxrdee	5	21	)	)	-RRB-
work_kwvyudrv4zalznxpzztokxrdee	5	22	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	5	23	whether	whether	IN
work_kwvyudrv4zalznxpzztokxrdee	5	24	financing	financing	NN
work_kwvyudrv4zalznxpzztokxrdee	5	25	is	be	VBZ
work_kwvyudrv4zalznxpzztokxrdee	5	26	a	a	DT
work_kwvyudrv4zalznxpzztokxrdee	5	27	county	county	NN
work_kwvyudrv4zalznxpzztokxrdee	5	28	(	(	-LRB-
work_kwvyudrv4zalznxpzztokxrdee	5	29	S	S	NNP
work_kwvyudrv4zalznxpzztokxrdee	5	30	)	)	-RRB-
work_kwvyudrv4zalznxpzztokxrdee	5	31	or	or	CC
work_kwvyudrv4zalznxpzztokxrdee	5	32	national	national	JJ
work_kwvyudrv4zalznxpzztokxrdee	5	33	(	(	-LRB-
work_kwvyudrv4zalznxpzztokxrdee	5	34	others	other	NNS
work_kwvyudrv4zalznxpzztokxrdee	5	35	)	)	-RRB-
work_kwvyudrv4zalznxpzztokxrdee	5	36	responsibility	responsibility	NN
work_kwvyudrv4zalznxpzztokxrdee	5	37	.	.	.
work_kwvyudrv4zalznxpzztokxrdee	6	1	All	all	DT
work_kwvyudrv4zalznxpzztokxrdee	6	2	have	have	VBP
work_kwvyudrv4zalznxpzztokxrdee	6	3	regulated	regulate	VBN
work_kwvyudrv4zalznxpzztokxrdee	6	4	prices	price	NNS
work_kwvyudrv4zalznxpzztokxrdee	6	5	for	for	IN
work_kwvyudrv4zalznxpzztokxrdee	6	6	reimbursed	reimburse	VBN
work_kwvyudrv4zalznxpzztokxrdee	6	7	drugs	drug	NNS
work_kwvyudrv4zalznxpzztokxrdee	6	8	;	;	,
work_kwvyudrv4zalznxpzztokxrdee	6	9	based	base	VBN
work_kwvyudrv4zalznxpzztokxrdee	6	10	either	either	CC
work_kwvyudrv4zalznxpzztokxrdee	6	11	upon	upon	IN
work_kwvyudrv4zalznxpzztokxrdee	6	12	international	international	JJ
work_kwvyudrv4zalznxpzztokxrdee	6	13	comparisons	comparison	NNS
work_kwvyudrv4zalznxpzztokxrdee	6	14	(	(	-LRB-
work_kwvyudrv4zalznxpzztokxrdee	6	15	N	n	NN
work_kwvyudrv4zalznxpzztokxrdee	6	16	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	6	17	D	d	NN
work_kwvyudrv4zalznxpzztokxrdee	6	18	)	)	-RRB-
work_kwvyudrv4zalznxpzztokxrdee	6	19	or	or	CC
work_kwvyudrv4zalznxpzztokxrdee	6	20	country	country	NN
work_kwvyudrv4zalznxpzztokxrdee	6	21	-	-	HYPH
work_kwvyudrv4zalznxpzztokxrdee	6	22	specific	specific	JJ
work_kwvyudrv4zalznxpzztokxrdee	6	23	decisions	decision	NNS
work_kwvyudrv4zalznxpzztokxrdee	6	24	(	(	-LRB-
work_kwvyudrv4zalznxpzztokxrdee	6	25	S	S	NNP
work_kwvyudrv4zalznxpzztokxrdee	6	26	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	6	27	F	F	NNP
work_kwvyudrv4zalznxpzztokxrdee	6	28	)	)	-RRB-
work_kwvyudrv4zalznxpzztokxrdee	6	29	.	.	.
work_kwvyudrv4zalznxpzztokxrdee	7	1	The	the	DT
work_kwvyudrv4zalznxpzztokxrdee	7	2	criteria	criterion	NNS
work_kwvyudrv4zalznxpzztokxrdee	7	3	used	use	VBD
work_kwvyudrv4zalznxpzztokxrdee	7	4	for	for	IN
work_kwvyudrv4zalznxpzztokxrdee	7	5	deciding	decide	VBG
work_kwvyudrv4zalznxpzztokxrdee	7	6	to	to	TO
work_kwvyudrv4zalznxpzztokxrdee	7	7	reimburse	reimburse	VB
work_kwvyudrv4zalznxpzztokxrdee	7	8	a	a	DT
work_kwvyudrv4zalznxpzztokxrdee	7	9	drug	drug	NN
work_kwvyudrv4zalznxpzztokxrdee	7	10	vary	vary	VBP
work_kwvyudrv4zalznxpzztokxrdee	7	11	between	between	IN
work_kwvyudrv4zalznxpzztokxrdee	7	12	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	7	13	countries	country	NNS
work_kwvyudrv4zalznxpzztokxrdee	7	14	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	7	15	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	7	16	reimbursement	reimbursement	NN
work_kwvyudrv4zalznxpzztokxrdee	7	17	is	be	VBZ
work_kwvyudrv4zalznxpzztokxrdee	7	18	practiced	practice	VBN
work_kwvyudrv4zalznxpzztokxrdee	7	19	differently	differently	RB
work_kwvyudrv4zalznxpzztokxrdee	7	20	in	in	IN
work_kwvyudrv4zalznxpzztokxrdee	7	21	several	several	JJ
work_kwvyudrv4zalznxpzztokxrdee	7	22	other	other	JJ
work_kwvyudrv4zalznxpzztokxrdee	7	23	dimensions	dimension	NNS
work_kwvyudrv4zalznxpzztokxrdee	7	24	:	:	:
work_kwvyudrv4zalznxpzztokxrdee	7	25	mandatory	mandatory	JJ
work_kwvyudrv4zalznxpzztokxrdee	7	26	requirement	requirement	NN
work_kwvyudrv4zalznxpzztokxrdee	7	27	for	for	IN
work_kwvyudrv4zalznxpzztokxrdee	7	28	pharmacoeconomic	pharmacoeconomic	JJ
work_kwvyudrv4zalznxpzztokxrdee	7	29	analysis	analysis	NN
work_kwvyudrv4zalznxpzztokxrdee	7	30	(	(	-LRB-
work_kwvyudrv4zalznxpzztokxrdee	7	31	F	F	NNP
work_kwvyudrv4zalznxpzztokxrdee	7	32	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	7	33	N	N	NNP
work_kwvyudrv4zalznxpzztokxrdee	7	34	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	7	35	S	S	NNP
work_kwvyudrv4zalznxpzztokxrdee	7	36	)	)	-RRB-
work_kwvyudrv4zalznxpzztokxrdee	7	37	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	7	38	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	7	39	existence	existence	NN
work_kwvyudrv4zalznxpzztokxrdee	7	40	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	7	41	patient	patient	JJ
work_kwvyudrv4zalznxpzztokxrdee	7	42	-	-	HYPH
work_kwvyudrv4zalznxpzztokxrdee	7	43	specific	specific	JJ
work_kwvyudrv4zalznxpzztokxrdee	7	44	reimbursement	reimbursement	NN
work_kwvyudrv4zalznxpzztokxrdee	7	45	systems	system	NNS
work_kwvyudrv4zalznxpzztokxrdee	7	46	(	(	-LRB-
work_kwvyudrv4zalznxpzztokxrdee	7	47	D	D	NNP
work_kwvyudrv4zalznxpzztokxrdee	7	48	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	7	49	F	F	NNP
work_kwvyudrv4zalznxpzztokxrdee	7	50	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	7	51	N	N	NNP
work_kwvyudrv4zalznxpzztokxrdee	7	52	)	)	-RRB-
work_kwvyudrv4zalznxpzztokxrdee	7	53	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	7	54	product-	product-	JJ
work_kwvyudrv4zalznxpzztokxrdee	7	55	(	(	-LRB-
work_kwvyudrv4zalznxpzztokxrdee	7	56	S	s	NN
work_kwvyudrv4zalznxpzztokxrdee	7	57	)	)	-RRB-
work_kwvyudrv4zalznxpzztokxrdee	7	58	or	or	CC
work_kwvyudrv4zalznxpzztokxrdee	7	59	indication	indication	NN
work_kwvyudrv4zalznxpzztokxrdee	7	60	-	-	HYPH
work_kwvyudrv4zalznxpzztokxrdee	7	61	based	base	VBN
work_kwvyudrv4zalznxpzztokxrdee	7	62	(	(	-LRB-
work_kwvyudrv4zalznxpzztokxrdee	7	63	others	other	NNS
work_kwvyudrv4zalznxpzztokxrdee	7	64	)	)	-RRB-
work_kwvyudrv4zalznxpzztokxrdee	7	65	reimbursement	reimbursement	NN
work_kwvyudrv4zalznxpzztokxrdee	7	66	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	7	67	use	use	NN
work_kwvyudrv4zalznxpzztokxrdee	7	68	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	7	69	graded	graded	JJ
work_kwvyudrv4zalznxpzztokxrdee	7	70	(	(	-LRB-
work_kwvyudrv4zalznxpzztokxrdee	7	71	F	f	NN
work_kwvyudrv4zalznxpzztokxrdee	7	72	)	)	-RRB-
work_kwvyudrv4zalznxpzztokxrdee	7	73	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	7	74	conditional	conditional	JJ
work_kwvyudrv4zalznxpzztokxrdee	7	75	(	(	-LRB-
work_kwvyudrv4zalznxpzztokxrdee	7	76	N	n	NN
work_kwvyudrv4zalznxpzztokxrdee	7	77	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	7	78	S	s	NN
work_kwvyudrv4zalznxpzztokxrdee	7	79	)	)	-RRB-
work_kwvyudrv4zalznxpzztokxrdee	7	80	or	or	CC
work_kwvyudrv4zalznxpzztokxrdee	7	81	temporary	temporary	JJ
work_kwvyudrv4zalznxpzztokxrdee	7	82	(	(	-LRB-
work_kwvyudrv4zalznxpzztokxrdee	7	83	S	s	NN
work_kwvyudrv4zalznxpzztokxrdee	7	84	)	)	-RRB-
work_kwvyudrv4zalznxpzztokxrdee	7	85	reimbursement	reimbursement	NN
work_kwvyudrv4zalznxpzztokxrdee	7	86	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	7	87	use	use	NN
work_kwvyudrv4zalznxpzztokxrdee	7	88	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	7	89	reimbursement	reimbursement	NN
work_kwvyudrv4zalznxpzztokxrdee	7	90	contracts	contract	NNS
work_kwvyudrv4zalznxpzztokxrdee	7	91	(	(	-LRB-
work_kwvyudrv4zalznxpzztokxrdee	7	92	N	n	NN
work_kwvyudrv4zalznxpzztokxrdee	7	93	)	)	-RRB-
work_kwvyudrv4zalznxpzztokxrdee	7	94	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	7	95	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	7	96	different	different	JJ
work_kwvyudrv4zalznxpzztokxrdee	7	97	processes	process	NNS
work_kwvyudrv4zalznxpzztokxrdee	7	98	for	for	IN
work_kwvyudrv4zalznxpzztokxrdee	7	99	handling	handle	VBG
work_kwvyudrv4zalznxpzztokxrdee	7	100	disagreement	disagreement	NN
work_kwvyudrv4zalznxpzztokxrdee	7	101	about	about	IN
work_kwvyudrv4zalznxpzztokxrdee	7	102	decisions	decision	NNS
work_kwvyudrv4zalznxpzztokxrdee	7	103	.	.	.
work_kwvyudrv4zalznxpzztokxrdee	8	1	CONCLUSION	conclusion	NN
work_kwvyudrv4zalznxpzztokxrdee	8	2	:	:	:
work_kwvyudrv4zalznxpzztokxrdee	8	3	The	the	DT
work_kwvyudrv4zalznxpzztokxrdee	8	4	Nordic	nordic	JJ
work_kwvyudrv4zalznxpzztokxrdee	8	5	countries	country	NNS
work_kwvyudrv4zalznxpzztokxrdee	8	6	all	all	DT
work_kwvyudrv4zalznxpzztokxrdee	8	7	have	have	VBP
work_kwvyudrv4zalznxpzztokxrdee	8	8	a	a	DT
work_kwvyudrv4zalznxpzztokxrdee	8	9	national	national	JJ
work_kwvyudrv4zalznxpzztokxrdee	8	10	health	health	NN
work_kwvyudrv4zalznxpzztokxrdee	8	11	care	care	NN
work_kwvyudrv4zalznxpzztokxrdee	8	12	system	system	NN
work_kwvyudrv4zalznxpzztokxrdee	8	13	financed	finance	VBN
work_kwvyudrv4zalznxpzztokxrdee	8	14	by	by	IN
work_kwvyudrv4zalznxpzztokxrdee	8	15	taxation	taxation	NN
work_kwvyudrv4zalznxpzztokxrdee	8	16	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	8	17	encompassing	encompass	VBG
work_kwvyudrv4zalznxpzztokxrdee	8	18	prescription	prescription	NN
work_kwvyudrv4zalznxpzztokxrdee	8	19	drugs	drug	NNS
work_kwvyudrv4zalznxpzztokxrdee	8	20	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	8	21	but	but	CC
work_kwvyudrv4zalznxpzztokxrdee	8	22	differ	differ	VB
work_kwvyudrv4zalznxpzztokxrdee	8	23	in	in	IN
work_kwvyudrv4zalznxpzztokxrdee	8	24	a	a	DT
work_kwvyudrv4zalznxpzztokxrdee	8	25	number	number	NN
work_kwvyudrv4zalznxpzztokxrdee	8	26	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	8	27	other	other	JJ
work_kwvyudrv4zalznxpzztokxrdee	8	28	dimensions	dimension	NNS
work_kwvyudrv4zalznxpzztokxrdee	8	29	with	with	IN
work_kwvyudrv4zalznxpzztokxrdee	8	30	respect	respect	NN
work_kwvyudrv4zalznxpzztokxrdee	8	31	to	to	IN
work_kwvyudrv4zalznxpzztokxrdee	8	32	financing	financing	NN
work_kwvyudrv4zalznxpzztokxrdee	8	33	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	8	34	pricing	pricing	NN
work_kwvyudrv4zalznxpzztokxrdee	8	35	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	8	36	reimbursing	reimburse	VBG
work_kwvyudrv4zalznxpzztokxrdee	8	37	such	such	JJ
work_kwvyudrv4zalznxpzztokxrdee	8	38	drugs	drug	NNS
work_kwvyudrv4zalznxpzztokxrdee	8	39	.	.	.
work_kwvyudrv4zalznxpzztokxrdee	9	1	PHP24	PHP24	NNP
work_kwvyudrv4zalznxpzztokxrdee	9	2	A	a	DT
work_kwvyudrv4zalznxpzztokxrdee	9	3	SYSTEMATIC	systematic	JJ
work_kwvyudrv4zalznxpzztokxrdee	9	4	REVIEW	REVIEW	NNP
work_kwvyudrv4zalznxpzztokxrdee	9	5	OF	of	IN
work_kwvyudrv4zalznxpzztokxrdee	9	6	THE	the	DT
work_kwvyudrv4zalznxpzztokxrdee	9	7	EUROPEAN	EUROPEAN	NNP
work_kwvyudrv4zalznxpzztokxrdee	9	8	PHARMACEUTICAL	PHARMACEUTICAL	NNP
work_kwvyudrv4zalznxpzztokxrdee	9	9	MARKET	MARKET	NNP
work_kwvyudrv4zalznxpzztokxrdee	9	10	AND	and	CC
work_kwvyudrv4zalznxpzztokxrdee	9	11	THE	the	DT
work_kwvyudrv4zalznxpzztokxrdee	9	12	IMPACT	IMPACT	NNP
work_kwvyudrv4zalznxpzztokxrdee	9	13	OF	of	IN
work_kwvyudrv4zalznxpzztokxrdee	9	14	EUROPEAN	EUROPEAN	NNP
work_kwvyudrv4zalznxpzztokxrdee	9	15	UNION	UNION	NNP
work_kwvyudrv4zalznxpzztokxrdee	9	16	REGULATION	REGULATION	NNP
work_kwvyudrv4zalznxpzztokxrdee	9	17	AND	and	CC
work_kwvyudrv4zalznxpzztokxrdee	9	18	JURISDICTION	JURISDICTION	NNP
work_kwvyudrv4zalznxpzztokxrdee	9	19	Van	Van	NNP
work_kwvyudrv4zalznxpzztokxrdee	9	20	Ginneken	Ginneken	NNP
work_kwvyudrv4zalznxpzztokxrdee	9	21	EJ	EJ	NNP
work_kwvyudrv4zalznxpzztokxrdee	9	22	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	9	23	Schreyögg	Schreyögg	NNP
work_kwvyudrv4zalznxpzztokxrdee	9	24	J	J	NNP
work_kwvyudrv4zalznxpzztokxrdee	9	25	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	9	26	Gericke	Gericke	NNP
work_kwvyudrv4zalznxpzztokxrdee	9	27	CA	CA	NNP
work_kwvyudrv4zalznxpzztokxrdee	9	28	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	9	29	Busse	Busse	NNP
work_kwvyudrv4zalznxpzztokxrdee	9	30	R	R	NNP
work_kwvyudrv4zalznxpzztokxrdee	9	31	Berlin	Berlin	NNP
work_kwvyudrv4zalznxpzztokxrdee	9	32	University	University	NNP
work_kwvyudrv4zalznxpzztokxrdee	9	33	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	9	34	Technology	Technology	NNP
work_kwvyudrv4zalznxpzztokxrdee	9	35	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	9	36	Berlin	Berlin	NNP
work_kwvyudrv4zalznxpzztokxrdee	9	37	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	9	38	Germany	Germany	NNP
work_kwvyudrv4zalznxpzztokxrdee	9	39	OBJECTIVES	OBJECTIVES	NNP
work_kwvyudrv4zalznxpzztokxrdee	9	40	:	:	:
work_kwvyudrv4zalznxpzztokxrdee	9	41	To	to	TO
work_kwvyudrv4zalznxpzztokxrdee	9	42	examine	examine	VB
work_kwvyudrv4zalznxpzztokxrdee	9	43	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	9	44	impact	impact	NN
work_kwvyudrv4zalznxpzztokxrdee	9	45	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	9	46	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	9	47	increasing	increase	VBG
work_kwvyudrv4zalznxpzztokxrdee	9	48	role	role	NN
work_kwvyudrv4zalznxpzztokxrdee	9	49	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	9	50	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	9	51	European	European	NNP
work_kwvyudrv4zalznxpzztokxrdee	9	52	Union	Union	NNP
work_kwvyudrv4zalznxpzztokxrdee	9	53	(	(	-LRB-
work_kwvyudrv4zalznxpzztokxrdee	9	54	EU	EU	NNP
work_kwvyudrv4zalznxpzztokxrdee	9	55	)	)	-RRB-
work_kwvyudrv4zalznxpzztokxrdee	9	56	on	on	IN
work_kwvyudrv4zalznxpzztokxrdee	9	57	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	9	58	European	european	JJ
work_kwvyudrv4zalznxpzztokxrdee	9	59	pharmaceutical	pharmaceutical	NN
work_kwvyudrv4zalznxpzztokxrdee	9	60	market	market	NN
work_kwvyudrv4zalznxpzztokxrdee	9	61	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	9	62	focusing	focus	VBG
work_kwvyudrv4zalznxpzztokxrdee	9	63	on	on	IN
work_kwvyudrv4zalznxpzztokxrdee	9	64	industry	industry	NN
work_kwvyudrv4zalznxpzztokxrdee	9	65	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	9	66	national	national	JJ
work_kwvyudrv4zalznxpzztokxrdee	9	67	policies	policy	NNS
work_kwvyudrv4zalznxpzztokxrdee	9	68	.	.	.
work_kwvyudrv4zalznxpzztokxrdee	10	1	To	to	TO
work_kwvyudrv4zalznxpzztokxrdee	10	2	give	give	VB
work_kwvyudrv4zalznxpzztokxrdee	10	3	a	a	DT
work_kwvyudrv4zalznxpzztokxrdee	10	4	sys-	sys-	NN
work_kwvyudrv4zalznxpzztokxrdee	10	5	tematic	tematic	JJ
work_kwvyudrv4zalznxpzztokxrdee	10	6	overview	overview	NN
work_kwvyudrv4zalznxpzztokxrdee	10	7	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	10	8	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	10	9	current	current	JJ
work_kwvyudrv4zalznxpzztokxrdee	10	10	state	state	NN
work_kwvyudrv4zalznxpzztokxrdee	10	11	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	10	12	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	10	13	European	european	JJ
work_kwvyudrv4zalznxpzztokxrdee	10	14	pharma-	pharma-	JJ
work_kwvyudrv4zalznxpzztokxrdee	10	15	ceutical	ceutical	JJ
work_kwvyudrv4zalznxpzztokxrdee	10	16	market	market	NN
work_kwvyudrv4zalznxpzztokxrdee	10	17	as	as	IN
work_kwvyudrv4zalznxpzztokxrdee	10	18	a	a	DT
work_kwvyudrv4zalznxpzztokxrdee	10	19	whole	whole	NN
work_kwvyudrv4zalznxpzztokxrdee	10	20	.	.	.
work_kwvyudrv4zalznxpzztokxrdee	11	1	METHODS	methods	JJ
work_kwvyudrv4zalznxpzztokxrdee	11	2	:	:	:
work_kwvyudrv4zalznxpzztokxrdee	11	3	Systematic	systematic	JJ
work_kwvyudrv4zalznxpzztokxrdee	11	4	literature	literature	NN
work_kwvyudrv4zalznxpzztokxrdee	11	5	review	review	NN
work_kwvyudrv4zalznxpzztokxrdee	11	6	for	for	IN
work_kwvyudrv4zalznxpzztokxrdee	11	7	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	11	8	years	year	NNS
work_kwvyudrv4zalznxpzztokxrdee	11	9	1965–2005	1965–2005	CD
work_kwvyudrv4zalznxpzztokxrdee	11	10	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	11	11	including	include	VBG
work_kwvyudrv4zalznxpzztokxrdee	11	12	“	"	``
work_kwvyudrv4zalznxpzztokxrdee	11	13	grey	grey	NNP
work_kwvyudrv4zalznxpzztokxrdee	11	14	”	"	''
work_kwvyudrv4zalznxpzztokxrdee	11	15	sources	source	NNS
work_kwvyudrv4zalznxpzztokxrdee	11	16	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	11	17	information	information	NN
work_kwvyudrv4zalznxpzztokxrdee	11	18	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	11	19	online	online	JJ
work_kwvyudrv4zalznxpzztokxrdee	11	20	databases	database	NNS
work_kwvyudrv4zalznxpzztokxrdee	11	21	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	11	22	European	European	NNP
work_kwvyudrv4zalznxpzztokxrdee	11	23	Commission	Commission	NNP
work_kwvyudrv4zalznxpzztokxrdee	11	24	docu-	docu-	NN
work_kwvyudrv4zalznxpzztokxrdee	11	25	ments	ment	NNS
work_kwvyudrv4zalznxpzztokxrdee	11	26	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	11	27	European	European	NNP
work_kwvyudrv4zalznxpzztokxrdee	11	28	Court	Court	NNP
work_kwvyudrv4zalznxpzztokxrdee	11	29	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	11	30	Justice	Justice	NNP
work_kwvyudrv4zalznxpzztokxrdee	11	31	rulings	ruling	NNS
work_kwvyudrv4zalznxpzztokxrdee	11	32	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	11	33	relevant	relevant	JJ
work_kwvyudrv4zalznxpzztokxrdee	11	34	journals	journal	NNS
work_kwvyudrv4zalznxpzztokxrdee	11	35	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	11	36	systematically	systematically	RB
work_kwvyudrv4zalznxpzztokxrdee	11	37	tracing	trace	VBG
work_kwvyudrv4zalznxpzztokxrdee	11	38	back	back	RP
work_kwvyudrv4zalznxpzztokxrdee	11	39	relevant	relevant	JJ
work_kwvyudrv4zalznxpzztokxrdee	11	40	references	reference	NNS
work_kwvyudrv4zalznxpzztokxrdee	11	41	.	.	.
work_kwvyudrv4zalznxpzztokxrdee	12	1	RESULTS	RESULTS	NNP
work_kwvyudrv4zalznxpzztokxrdee	12	2	:	:	:
work_kwvyudrv4zalznxpzztokxrdee	12	3	The	the	DT
work_kwvyudrv4zalznxpzztokxrdee	12	4	EU	EU	NNP
work_kwvyudrv4zalznxpzztokxrdee	12	5	attempts	attempt	VBZ
work_kwvyudrv4zalznxpzztokxrdee	12	6	to	to	TO
work_kwvyudrv4zalznxpzztokxrdee	12	7	liberalise	liberalise	VB
work_kwvyudrv4zalznxpzztokxrdee	12	8	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	12	9	pharmaceutical	pharmaceutical	JJ
work_kwvyudrv4zalznxpzztokxrdee	12	10	market	market	NN
work_kwvyudrv4zalznxpzztokxrdee	12	11	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	12	12	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	12	13	realisation	realisation	NN
work_kwvyudrv4zalznxpzztokxrdee	12	14	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	12	15	a	a	DT
work_kwvyudrv4zalznxpzztokxrdee	12	16	Single	single	JJ
work_kwvyudrv4zalznxpzztokxrdee	12	17	European	European	NNP
work_kwvyudrv4zalznxpzztokxrdee	12	18	Market	Market	NNP
work_kwvyudrv4zalznxpzztokxrdee	12	19	(	(	-LRB-
work_kwvyudrv4zalznxpzztokxrdee	12	20	SEM	SEM	NNP
work_kwvyudrv4zalznxpzztokxrdee	12	21	)	)	-RRB-
work_kwvyudrv4zalznxpzztokxrdee	12	22	came	come	VBD
work_kwvyudrv4zalznxpzztokxrdee	12	23	to	to	IN
work_kwvyudrv4zalznxpzztokxrdee	12	24	a	a	DT
work_kwvyudrv4zalznxpzztokxrdee	12	25	stand-	stand-	NN
work_kwvyudrv4zalznxpzztokxrdee	12	26	still	still	RB
work_kwvyudrv4zalznxpzztokxrdee	12	27	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	12	28	after	after	IN
work_kwvyudrv4zalznxpzztokxrdee	12	29	some	some	DT
work_kwvyudrv4zalznxpzztokxrdee	12	30	considerable	considerable	JJ
work_kwvyudrv4zalznxpzztokxrdee	12	31	achievements	achievement	NNS
work_kwvyudrv4zalznxpzztokxrdee	12	32	(	(	-LRB-
work_kwvyudrv4zalznxpzztokxrdee	12	33	e.g.	e.g.	RB
work_kwvyudrv4zalznxpzztokxrdee	13	1	marketing	marketing	NN
work_kwvyudrv4zalznxpzztokxrdee	13	2	authorisation	authorisation	NN
work_kwvyudrv4zalznxpzztokxrdee	13	3	)	)	-RRB-
work_kwvyudrv4zalznxpzztokxrdee	13	4	.	.	.
work_kwvyudrv4zalznxpzztokxrdee	14	1	Instead	instead	RB
work_kwvyudrv4zalznxpzztokxrdee	14	2	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	14	3	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	14	4	EU	EU	NNP
work_kwvyudrv4zalznxpzztokxrdee	14	5	seems	seem	VBZ
work_kwvyudrv4zalznxpzztokxrdee	14	6	to	to	TO
work_kwvyudrv4zalznxpzztokxrdee	14	7	concentrate	concentrate	VB
work_kwvyudrv4zalznxpzztokxrdee	14	8	on	on	IN
work_kwvyudrv4zalznxpzztokxrdee	14	9	coor-	coor-	JJ
work_kwvyudrv4zalznxpzztokxrdee	14	10	dination	dination	NN
work_kwvyudrv4zalznxpzztokxrdee	14	11	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	14	12	results	result	NNS
work_kwvyudrv4zalznxpzztokxrdee	14	13	through	through	IN
work_kwvyudrv4zalznxpzztokxrdee	14	14	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	14	15	adoption	adoption	NN
work_kwvyudrv4zalznxpzztokxrdee	14	16	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	14	17	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	14	18	so	so	RB
work_kwvyudrv4zalznxpzztokxrdee	14	19	-	-	HYPH
work_kwvyudrv4zalznxpzztokxrdee	14	20	called	call	VBN
work_kwvyudrv4zalznxpzztokxrdee	14	21	G10	G10	NNP
work_kwvyudrv4zalznxpzztokxrdee	14	22	recommendations	recommendation	NNS
work_kwvyudrv4zalznxpzztokxrdee	14	23	.	.	.
work_kwvyudrv4zalznxpzztokxrdee	15	1	EU	EU	NNP
work_kwvyudrv4zalznxpzztokxrdee	15	2	Member	Member	NNP
work_kwvyudrv4zalznxpzztokxrdee	15	3	States	States	NNP
work_kwvyudrv4zalznxpzztokxrdee	15	4	successfully	successfully	RB
work_kwvyudrv4zalznxpzztokxrdee	15	5	—	—	:
work_kwvyudrv4zalznxpzztokxrdee	15	6	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	15	7	inten-	inten-	XX
work_kwvyudrv4zalznxpzztokxrdee	15	8	tionally	tionally	RB
work_kwvyudrv4zalznxpzztokxrdee	15	9	—	—	:
work_kwvyudrv4zalznxpzztokxrdee	15	10	kept	keep	VBD
work_kwvyudrv4zalznxpzztokxrdee	15	11	control	control	NN
work_kwvyudrv4zalznxpzztokxrdee	15	12	on	on	IN
work_kwvyudrv4zalznxpzztokxrdee	15	13	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	15	14	issues	issue	NNS
work_kwvyudrv4zalznxpzztokxrdee	15	15	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	15	16	pricing	pricing	NN
work_kwvyudrv4zalznxpzztokxrdee	15	17	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	15	18	reimbursement	reimbursement	NN
work_kwvyudrv4zalznxpzztokxrdee	15	19	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	15	20	pharmacies	pharmacy	NNS
work_kwvyudrv4zalznxpzztokxrdee	15	21	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	15	22	prescribing	prescribing	NN
work_kwvyudrv4zalznxpzztokxrdee	15	23	.	.	.
work_kwvyudrv4zalznxpzztokxrdee	16	1	Over	over	IN
work_kwvyudrv4zalznxpzztokxrdee	16	2	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	16	3	last	last	JJ
work_kwvyudrv4zalznxpzztokxrdee	16	4	25	25	CD
work_kwvyudrv4zalznxpzztokxrdee	16	5	years	year	NNS
work_kwvyudrv4zalznxpzztokxrdee	16	6	they	-PRON-	PRP
work_kwvyudrv4zalznxpzztokxrdee	16	7	adapted	adapt	VBD
work_kwvyudrv4zalznxpzztokxrdee	16	8	increasingly	increasingly	RB
work_kwvyudrv4zalznxpzztokxrdee	16	9	convergent	convergent	NN
work_kwvyudrv4zalznxpzztokxrdee	16	10	measures	measure	NNS
work_kwvyudrv4zalznxpzztokxrdee	16	11	to	to	TO
work_kwvyudrv4zalznxpzztokxrdee	16	12	cope	cope	VB
work_kwvyudrv4zalznxpzztokxrdee	16	13	with	with	IN
work_kwvyudrv4zalznxpzztokxrdee	16	14	rising	rise	VBG
work_kwvyudrv4zalznxpzztokxrdee	16	15	pharma-	pharma-	JJ
work_kwvyudrv4zalznxpzztokxrdee	16	16	ceutical	ceutical	JJ
work_kwvyudrv4zalznxpzztokxrdee	16	17	expenditures	expenditure	NNS
work_kwvyudrv4zalznxpzztokxrdee	16	18	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	16	19	without	without	IN
work_kwvyudrv4zalznxpzztokxrdee	16	20	long	long	RB
work_kwvyudrv4zalznxpzztokxrdee	16	21	-	-	HYPH
work_kwvyudrv4zalznxpzztokxrdee	16	22	lasting	last	VBG
work_kwvyudrv4zalznxpzztokxrdee	16	23	cost	cost	NN
work_kwvyudrv4zalznxpzztokxrdee	16	24	containment	containment	NN
work_kwvyudrv4zalznxpzztokxrdee	16	25	effects	effect	NNS
work_kwvyudrv4zalznxpzztokxrdee	16	26	.	.	.
work_kwvyudrv4zalznxpzztokxrdee	17	1	However	however	RB
work_kwvyudrv4zalznxpzztokxrdee	17	2	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	17	3	recent	recent	JJ
work_kwvyudrv4zalznxpzztokxrdee	17	4	European	european	JJ
work_kwvyudrv4zalznxpzztokxrdee	17	5	case	case	NN
work_kwvyudrv4zalznxpzztokxrdee	17	6	law	law	NN
work_kwvyudrv4zalznxpzztokxrdee	17	7	might	may	MD
work_kwvyudrv4zalznxpzztokxrdee	17	8	prove	prove	VB
work_kwvyudrv4zalznxpzztokxrdee	17	9	to	to	TO
work_kwvyudrv4zalznxpzztokxrdee	17	10	have	have	VB
work_kwvyudrv4zalznxpzztokxrdee	17	11	far	far	RB
work_kwvyudrv4zalznxpzztokxrdee	17	12	reaching	reach	VBG
work_kwvyudrv4zalznxpzztokxrdee	17	13	consequences	consequence	NNS
work_kwvyudrv4zalznxpzztokxrdee	17	14	on	on	IN
work_kwvyudrv4zalznxpzztokxrdee	17	15	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	17	16	provision	provision	NN
work_kwvyudrv4zalznxpzztokxrdee	17	17	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	17	18	medicines	medicine	NNS
work_kwvyudrv4zalznxpzztokxrdee	17	19	.	.	.
work_kwvyudrv4zalznxpzztokxrdee	18	1	The	the	DT
work_kwvyudrv4zalznxpzztokxrdee	18	2	European	european	JJ
work_kwvyudrv4zalznxpzztokxrdee	18	3	pharmaceutical	pharmaceutical	NN
work_kwvyudrv4zalznxpzztokxrdee	18	4	industry	industry	NN
work_kwvyudrv4zalznxpzztokxrdee	18	5	—	—	:
work_kwvyudrv4zalznxpzztokxrdee	18	6	although	although	IN
work_kwvyudrv4zalznxpzztokxrdee	18	7	profitable	profitable	JJ
work_kwvyudrv4zalznxpzztokxrdee	18	8	—	—	:
work_kwvyudrv4zalznxpzztokxrdee	18	9	is	be	VBZ
work_kwvyudrv4zalznxpzztokxrdee	18	10	underperforming	underperform	VBG
work_kwvyudrv4zalznxpzztokxrdee	18	11	compared	compare	VBN
work_kwvyudrv4zalznxpzztokxrdee	18	12	to	to	IN
work_kwvyudrv4zalznxpzztokxrdee	18	13	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	18	14	USA	USA	NNP
work_kwvyudrv4zalznxpzztokxrdee	18	15	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	18	16	which	which	WDT
work_kwvyudrv4zalznxpzztokxrdee	18	17	is	be	VBZ
work_kwvyudrv4zalznxpzztokxrdee	18	18	blamed	blame	VBN
work_kwvyudrv4zalznxpzztokxrdee	18	19	on	on	IN
work_kwvyudrv4zalznxpzztokxrdee	18	20	restrictive	restrictive	JJ
work_kwvyudrv4zalznxpzztokxrdee	18	21	regulatory	regulatory	JJ
work_kwvyudrv4zalznxpzztokxrdee	18	22	frameworks	framework	NNS
work_kwvyudrv4zalznxpzztokxrdee	18	23	in	in	IN
work_kwvyudrv4zalznxpzztokxrdee	18	24	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	18	25	Member	Member	NNP
work_kwvyudrv4zalznxpzztokxrdee	18	26	States	States	NNPS
work_kwvyudrv4zalznxpzztokxrdee	18	27	.	.	.
work_kwvyudrv4zalznxpzztokxrdee	19	1	CON-	con-	JJ
work_kwvyudrv4zalznxpzztokxrdee	19	2	CLUSIONS	clusion	NNS
work_kwvyudrv4zalznxpzztokxrdee	19	3	:	:	:
work_kwvyudrv4zalznxpzztokxrdee	19	4	The	the	DT
work_kwvyudrv4zalznxpzztokxrdee	19	5	future	future	NN
work_kwvyudrv4zalznxpzztokxrdee	19	6	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	19	7	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	19	8	actors	actor	NNS
work_kwvyudrv4zalznxpzztokxrdee	19	9	in	in	IN
work_kwvyudrv4zalznxpzztokxrdee	19	10	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	19	11	European	european	JJ
work_kwvyudrv4zalznxpzztokxrdee	19	12	pharma-	pharma-	JJ
work_kwvyudrv4zalznxpzztokxrdee	19	13	ceutical	ceutical	JJ
work_kwvyudrv4zalznxpzztokxrdee	19	14	market	market	NN
work_kwvyudrv4zalznxpzztokxrdee	19	15	is	be	VBZ
work_kwvyudrv4zalznxpzztokxrdee	19	16	not	not	RB
work_kwvyudrv4zalznxpzztokxrdee	19	17	clear	clear	JJ
work_kwvyudrv4zalznxpzztokxrdee	19	18	.	.	.
work_kwvyudrv4zalznxpzztokxrdee	20	1	Will	Will	MD
work_kwvyudrv4zalznxpzztokxrdee	20	2	it	-PRON-	PRP
work_kwvyudrv4zalznxpzztokxrdee	20	3	bring	bring	VB
work_kwvyudrv4zalznxpzztokxrdee	20	4	more	more	JJR
work_kwvyudrv4zalznxpzztokxrdee	20	5	European	european	JJ
work_kwvyudrv4zalznxpzztokxrdee	20	6	influence	influence	NN
work_kwvyudrv4zalznxpzztokxrdee	20	7	or	or	CC
work_kwvyudrv4zalznxpzztokxrdee	20	8	a	a	DT
work_kwvyudrv4zalznxpzztokxrdee	20	9	strengthening	strengthening	NN
work_kwvyudrv4zalznxpzztokxrdee	20	10	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	20	11	national	national	JJ
work_kwvyudrv4zalznxpzztokxrdee	20	12	influence	influence	NN
work_kwvyudrv4zalznxpzztokxrdee	20	13	?	?	.
work_kwvyudrv4zalznxpzztokxrdee	21	1	In	in	IN
work_kwvyudrv4zalznxpzztokxrdee	21	2	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	21	3	short	short	JJ
work_kwvyudrv4zalznxpzztokxrdee	21	4	term	term	NN
work_kwvyudrv4zalznxpzztokxrdee	21	5	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	21	6	major	major	JJ
work_kwvyudrv4zalznxpzztokxrdee	21	7	change	change	NN
work_kwvyudrv4zalznxpzztokxrdee	21	8	towards	towards	IN
work_kwvyudrv4zalznxpzztokxrdee	21	9	a	a	DT
work_kwvyudrv4zalznxpzztokxrdee	21	10	SEM	SEM	NNP
work_kwvyudrv4zalznxpzztokxrdee	21	11	seems	seem	VBZ
work_kwvyudrv4zalznxpzztokxrdee	21	12	unlikely	unlikely	JJ
work_kwvyudrv4zalznxpzztokxrdee	21	13	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	21	14	but	but	CC
work_kwvyudrv4zalznxpzztokxrdee	21	15	in	in	IN
work_kwvyudrv4zalznxpzztokxrdee	21	16	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	21	17	longer	long	JJR
work_kwvyudrv4zalznxpzztokxrdee	21	18	term	term	NN
work_kwvyudrv4zalznxpzztokxrdee	21	19	European	european	JJ
work_kwvyudrv4zalznxpzztokxrdee	21	20	history	history	NN
work_kwvyudrv4zalznxpzztokxrdee	21	21	showed	show	VBD
work_kwvyudrv4zalznxpzztokxrdee	21	22	that	that	IN
work_kwvyudrv4zalznxpzztokxrdee	21	23	major	major	JJ
work_kwvyudrv4zalznxpzztokxrdee	21	24	change	change	NN
work_kwvyudrv4zalznxpzztokxrdee	21	25	is	be	VBZ
work_kwvyudrv4zalznxpzztokxrdee	21	26	pos-	pos-	VBN
work_kwvyudrv4zalznxpzztokxrdee	21	27	sible	sible	JJ
work_kwvyudrv4zalznxpzztokxrdee	21	28	.	.	.
work_kwvyudrv4zalznxpzztokxrdee	22	1	It	-PRON-	PRP
work_kwvyudrv4zalznxpzztokxrdee	22	2	seems	seem	VBZ
work_kwvyudrv4zalznxpzztokxrdee	22	3	clear	clear	JJ
work_kwvyudrv4zalznxpzztokxrdee	22	4	that	that	IN
work_kwvyudrv4zalznxpzztokxrdee	22	5	much	much	JJ
work_kwvyudrv4zalznxpzztokxrdee	22	6	depends	depend	VBZ
work_kwvyudrv4zalznxpzztokxrdee	22	7	on	on	IN
work_kwvyudrv4zalznxpzztokxrdee	22	8	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	22	9	attitude	attitude	NN
work_kwvyudrv4zalznxpzztokxrdee	22	10	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	22	11	Member	Member	NNP
work_kwvyudrv4zalznxpzztokxrdee	22	12	States	States	NNP
work_kwvyudrv4zalznxpzztokxrdee	22	13	towards	towards	IN
work_kwvyudrv4zalznxpzztokxrdee	22	14	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	22	15	new	new	JJ
work_kwvyudrv4zalznxpzztokxrdee	22	16	approach	approach	NN
work_kwvyudrv4zalznxpzztokxrdee	22	17	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	22	18	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	22	19	interpretation	interpretation	NN
work_kwvyudrv4zalznxpzztokxrdee	22	20	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	22	21	influence	influence	NN
work_kwvyudrv4zalznxpzztokxrdee	22	22	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	22	23	European	european	JJ
work_kwvyudrv4zalznxpzztokxrdee	22	24	case	case	NN
work_kwvyudrv4zalznxpzztokxrdee	22	25	law	law	NN
work_kwvyudrv4zalznxpzztokxrdee	22	26	.	.	.
work_kwvyudrv4zalznxpzztokxrdee	23	1	For	for	IN
work_kwvyudrv4zalznxpzztokxrdee	23	2	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	23	3	European	european	JJ
work_kwvyudrv4zalznxpzztokxrdee	23	4	industry	industry	NN
work_kwvyudrv4zalznxpzztokxrdee	23	5	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	23	6	adoption	adoption	NN
work_kwvyudrv4zalznxpzztokxrdee	23	7	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	23	8	implementation	implementation	NN
work_kwvyudrv4zalznxpzztokxrdee	23	9	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	23	10	G10	G10	NNP
work_kwvyudrv4zalznxpzztokxrdee	23	11	recommendations	recommendation	NNS
work_kwvyudrv4zalznxpzztokxrdee	23	12	is	be	VBZ
work_kwvyudrv4zalznxpzztokxrdee	23	13	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	23	14	great	great	JJ
work_kwvyudrv4zalznxpzztokxrdee	23	15	importance	importance	NN
work_kwvyudrv4zalznxpzztokxrdee	23	16	for	for	IN
work_kwvyudrv4zalznxpzztokxrdee	23	17	future	future	JJ
work_kwvyudrv4zalznxpzztokxrdee	23	18	competition	competition	NN
work_kwvyudrv4zalznxpzztokxrdee	23	19	with	with	IN
work_kwvyudrv4zalznxpzztokxrdee	23	20	US	US	NNP
work_kwvyudrv4zalznxpzztokxrdee	23	21	-	-	HYPH
work_kwvyudrv4zalznxpzztokxrdee	23	22	based	base	VBN
work_kwvyudrv4zalznxpzztokxrdee	23	23	companies	company	NNS
work_kwvyudrv4zalznxpzztokxrdee	23	24	.	.	.
work_kwvyudrv4zalznxpzztokxrdee	24	1	PHP25	PHP25	NNP
work_kwvyudrv4zalznxpzztokxrdee	24	2	USING	USING	NNP
work_kwvyudrv4zalznxpzztokxrdee	24	3	AN	an	DT
work_kwvyudrv4zalznxpzztokxrdee	24	4	ITALIAN	ITALIAN	NNP
work_kwvyudrv4zalznxpzztokxrdee	24	5	POPULATION	population	NN
work_kwvyudrv4zalznxpzztokxrdee	24	6	DATABASE	database	NN
work_kwvyudrv4zalznxpzztokxrdee	24	7	TO	to	IN
work_kwvyudrv4zalznxpzztokxrdee	24	8	PROFILE	PROFILE	NNP
work_kwvyudrv4zalznxpzztokxrdee	24	9	PREVALENCE	PREVALENCE	NNP
work_kwvyudrv4zalznxpzztokxrdee	24	10	AND	and	CC
work_kwvyudrv4zalznxpzztokxrdee	24	11	COSTS	costs	NN
work_kwvyudrv4zalznxpzztokxrdee	24	12	OF	of	IN
work_kwvyudrv4zalznxpzztokxrdee	24	13	CHRONIC	chronic	NN
work_kwvyudrv4zalznxpzztokxrdee	24	14	CONDITIONS	conditions	NN
work_kwvyudrv4zalznxpzztokxrdee	24	15	Yuen	Yuen	NNP
work_kwvyudrv4zalznxpzztokxrdee	24	16	EJ	EJ	NNP
work_kwvyudrv4zalznxpzztokxrdee	24	17	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	24	18	Maio	Maio	NNP
work_kwvyudrv4zalznxpzztokxrdee	24	19	V	V	NNP
work_kwvyudrv4zalznxpzztokxrdee	24	20	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	24	21	Louis	Louis	NNP
work_kwvyudrv4zalznxpzztokxrdee	24	22	DZ	DZ	NNP
work_kwvyudrv4zalznxpzztokxrdee	24	23	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	24	24	Rabinowitz	Rabinowitz	NNP
work_kwvyudrv4zalznxpzztokxrdee	24	25	C	C	NNP
work_kwvyudrv4zalznxpzztokxrdee	24	26	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	24	27	Robeson	Robeson	NNP
work_kwvyudrv4zalznxpzztokxrdee	24	28	M	M	NNP
work_kwvyudrv4zalznxpzztokxrdee	24	29	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	24	30	Smith	Smith	NNP
work_kwvyudrv4zalznxpzztokxrdee	24	31	KD	KD	NNP
work_kwvyudrv4zalznxpzztokxrdee	24	32	Jefferson	Jefferson	NNP
work_kwvyudrv4zalznxpzztokxrdee	24	33	Medical	Medical	NNP
work_kwvyudrv4zalznxpzztokxrdee	24	34	College	College	NNP
work_kwvyudrv4zalznxpzztokxrdee	24	35	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	24	36	Thomas	Thomas	NNP
work_kwvyudrv4zalznxpzztokxrdee	24	37	Jefferson	Jefferson	NNP
work_kwvyudrv4zalznxpzztokxrdee	24	38	University	University	NNP
work_kwvyudrv4zalznxpzztokxrdee	24	39	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	24	40	Philadelphia	Philadelphia	NNP
work_kwvyudrv4zalznxpzztokxrdee	24	41	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	24	42	PA	PA	NNP
work_kwvyudrv4zalznxpzztokxrdee	24	43	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	24	44	USA	USA	NNP
work_kwvyudrv4zalznxpzztokxrdee	24	45	OBJECTIVE	OBJECTIVE	NNP
work_kwvyudrv4zalznxpzztokxrdee	24	46	:	:	:
work_kwvyudrv4zalznxpzztokxrdee	24	47	Individuals	individual	NNS
work_kwvyudrv4zalznxpzztokxrdee	24	48	with	with	IN
work_kwvyudrv4zalznxpzztokxrdee	24	49	chronic	chronic	JJ
work_kwvyudrv4zalznxpzztokxrdee	24	50	medical	medical	JJ
work_kwvyudrv4zalznxpzztokxrdee	24	51	illness	illness	NN
work_kwvyudrv4zalznxpzztokxrdee	24	52	may	may	MD
work_kwvyudrv4zalznxpzztokxrdee	24	53	have	have	VB
work_kwvyudrv4zalznxpzztokxrdee	24	54	multiple	multiple	JJ
work_kwvyudrv4zalznxpzztokxrdee	24	55	health	health	NN
work_kwvyudrv4zalznxpzztokxrdee	24	56	problems	problem	NNS
work_kwvyudrv4zalznxpzztokxrdee	24	57	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	24	58	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	24	59	are	be	VBP
work_kwvyudrv4zalznxpzztokxrdee	24	60	often	often	RB
work_kwvyudrv4zalznxpzztokxrdee	24	61	costly	costly	JJ
work_kwvyudrv4zalznxpzztokxrdee	24	62	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	24	63	difficult	difficult	JJ
work_kwvyudrv4zalznxpzztokxrdee	24	64	to	to	TO
work_kwvyudrv4zalznxpzztokxrdee	24	65	manage	manage	VB
work_kwvyudrv4zalznxpzztokxrdee	24	66	.	.	.
work_kwvyudrv4zalznxpzztokxrdee	25	1	This	this	DT
work_kwvyudrv4zalznxpzztokxrdee	25	2	study	study	NN
work_kwvyudrv4zalznxpzztokxrdee	25	3	identifies	identify	VBZ
work_kwvyudrv4zalznxpzztokxrdee	25	4	those	those	DT
work_kwvyudrv4zalznxpzztokxrdee	25	5	with	with	IN
work_kwvyudrv4zalznxpzztokxrdee	25	6	highly	highly	RB
work_kwvyudrv4zalznxpzztokxrdee	25	7	prevalent	prevalent	JJ
work_kwvyudrv4zalznxpzztokxrdee	25	8	chronic	chronic	JJ
work_kwvyudrv4zalznxpzztokxrdee	25	9	conditions	condition	NNS
work_kwvyudrv4zalznxpzztokxrdee	25	10	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	25	11	assesses	assesse	NNS
work_kwvyudrv4zalznxpzztokxrdee	25	12	related	related	JJ
work_kwvyudrv4zalznxpzztokxrdee	25	13	health	health	NN
work_kwvyudrv4zalznxpzztokxrdee	25	14	service	service	NN
work_kwvyudrv4zalznxpzztokxrdee	25	15	use	use	NN
work_kwvyudrv4zalznxpzztokxrdee	25	16	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	25	17	costs	cost	NNS
work_kwvyudrv4zalznxpzztokxrdee	25	18	in	in	IN
work_kwvyudrv4zalznxpzztokxrdee	25	19	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	25	20	population	population	NN
work_kwvyudrv4zalznxpzztokxrdee	25	21	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	25	22	Emilia	Emilia	NNP
work_kwvyudrv4zalznxpzztokxrdee	25	23	Romagna	Romagna	NNP
work_kwvyudrv4zalznxpzztokxrdee	25	24	(	(	-LRB-
work_kwvyudrv4zalznxpzztokxrdee	25	25	RER	RER	NNP
work_kwvyudrv4zalznxpzztokxrdee	25	26	)	)	-RRB-
work_kwvyudrv4zalznxpzztokxrdee	25	27	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	25	28	a	a	DT
work_kwvyudrv4zalznxpzztokxrdee	25	29	large	large	JJ
work_kwvyudrv4zalznxpzztokxrdee	25	30	northern	northern	JJ
work_kwvyudrv4zalznxpzztokxrdee	25	31	Italian	italian	JJ
work_kwvyudrv4zalznxpzztokxrdee	25	32	region	region	NN
work_kwvyudrv4zalznxpzztokxrdee	25	33	.	.	.
work_kwvyudrv4zalznxpzztokxrdee	26	1	METHODS	METHODS	NNP
work_kwvyudrv4zalznxpzztokxrdee	26	2	:	:	:
work_kwvyudrv4zalznxpzztokxrdee	26	3	Pharmaceutical	pharmaceutical	NN
work_kwvyudrv4zalznxpzztokxrdee	26	4	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	26	5	hospital	hospital	NN
work_kwvyudrv4zalznxpzztokxrdee	26	6	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	26	7	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	26	8	demographic	demographic	JJ
work_kwvyudrv4zalznxpzztokxrdee	26	9	data	datum	NNS
work_kwvyudrv4zalznxpzztokxrdee	26	10	from	from	IN
work_kwvyudrv4zalznxpzztokxrdee	26	11	2000	2000	CD
work_kwvyudrv4zalznxpzztokxrdee	26	12	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	26	13	2001	2001	CD
work_kwvyudrv4zalznxpzztokxrdee	26	14	have	have	VBP
work_kwvyudrv4zalznxpzztokxrdee	26	15	been	be	VBN
work_kwvyudrv4zalznxpzztokxrdee	26	16	assembled	assemble	VBN
work_kwvyudrv4zalznxpzztokxrdee	26	17	for	for	IN
work_kwvyudrv4zalznxpzztokxrdee	26	18	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	26	19	entire	entire	JJ
work_kwvyudrv4zalznxpzztokxrdee	26	20	population	population	NN
work_kwvyudrv4zalznxpzztokxrdee	26	21	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	26	22	RER	RER	NNP
work_kwvyudrv4zalznxpzztokxrdee	26	23	(	(	-LRB-
work_kwvyudrv4zalznxpzztokxrdee	26	24	4	4	CD
work_kwvyudrv4zalznxpzztokxrdee	26	25	million	million	CD
work_kwvyudrv4zalznxpzztokxrdee	26	26	)	)	-RRB-
work_kwvyudrv4zalznxpzztokxrdee	26	27	.	.	.
work_kwvyudrv4zalznxpzztokxrdee	27	1	Pharmaceutical	pharmaceutical	NN
work_kwvyudrv4zalznxpzztokxrdee	27	2	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	27	3	hospital	hospital	NN
work_kwvyudrv4zalznxpzztokxrdee	27	4	tariffs	tariff	NNS
work_kwvyudrv4zalznxpzztokxrdee	27	5	were	be	VBD
work_kwvyudrv4zalznxpzztokxrdee	27	6	a	a	DT
work_kwvyudrv4zalznxpzztokxrdee	27	7	proxy	proxy	NN
work_kwvyudrv4zalznxpzztokxrdee	27	8	for	for	IN
work_kwvyudrv4zalznxpzztokxrdee	27	9	costs	cost	NNS
work_kwvyudrv4zalznxpzztokxrdee	27	10	.	.	.
work_kwvyudrv4zalznxpzztokxrdee	28	1	Pharmacy	pharmacy	NN
work_kwvyudrv4zalznxpzztokxrdee	28	2	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	28	3	hospital	hospital	NN
work_kwvyudrv4zalznxpzztokxrdee	28	4	records	record	NNS
work_kwvyudrv4zalznxpzztokxrdee	28	5	were	be	VBD
work_kwvyudrv4zalznxpzztokxrdee	28	6	used	use	VBN
work_kwvyudrv4zalznxpzztokxrdee	28	7	to	to	TO
work_kwvyudrv4zalznxpzztokxrdee	28	8	identify	identify	VB
work_kwvyudrv4zalznxpzztokxrdee	28	9	individual	individual	JJ
work_kwvyudrv4zalznxpzztokxrdee	28	10	morbidity	morbidity	NN
work_kwvyudrv4zalznxpzztokxrdee	28	11	.	.	.
work_kwvyudrv4zalznxpzztokxrdee	29	1	Data	datum	NNS
work_kwvyudrv4zalznxpzztokxrdee	29	2	included	include	VBD
work_kwvyudrv4zalznxpzztokxrdee	29	3	demo-	demo-	NNP
work_kwvyudrv4zalznxpzztokxrdee	29	4	graphic	graphic	JJ
work_kwvyudrv4zalznxpzztokxrdee	29	5	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	29	6	geographic	geographic	JJ
work_kwvyudrv4zalznxpzztokxrdee	29	7	information	information	NN
work_kwvyudrv4zalznxpzztokxrdee	29	8	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	29	9	encounter	encounter	NN
work_kwvyudrv4zalznxpzztokxrdee	29	10	dates	date	NNS
work_kwvyudrv4zalznxpzztokxrdee	29	11	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	29	12	diagno-	diagno-	VB
work_kwvyudrv4zalznxpzztokxrdee	29	13	sis	sis	NN
work_kwvyudrv4zalznxpzztokxrdee	29	14	/	/	SYM
work_kwvyudrv4zalznxpzztokxrdee	29	15	procedure	procedure	NN
work_kwvyudrv4zalznxpzztokxrdee	29	16	codes	code	NNS
work_kwvyudrv4zalznxpzztokxrdee	29	17	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	29	18	pharmaceutical	pharmaceutical	JJ
work_kwvyudrv4zalznxpzztokxrdee	29	19	information	information	NN
work_kwvyudrv4zalznxpzztokxrdee	29	20	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	29	21	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	29	22	health	health	NN
work_kwvyudrv4zalznxpzztokxrdee	29	23	care	care	NN
work_kwvyudrv4zalznxpzztokxrdee	29	24	costs	cost	NNS
work_kwvyudrv4zalznxpzztokxrdee	29	25	.	.	.
work_kwvyudrv4zalznxpzztokxrdee	30	1	Individuals	individual	NNS
work_kwvyudrv4zalznxpzztokxrdee	30	2	were	be	VBD
work_kwvyudrv4zalznxpzztokxrdee	30	3	classified	classify	VBN
work_kwvyudrv4zalznxpzztokxrdee	30	4	as	as	IN
work_kwvyudrv4zalznxpzztokxrdee	30	5	having	have	VBG
work_kwvyudrv4zalznxpzztokxrdee	30	6	a	a	DT
work_kwvyudrv4zalznxpzztokxrdee	30	7	chronic	chronic	JJ
work_kwvyudrv4zalznxpzztokxrdee	30	8	condi-	condi-	XX
work_kwvyudrv4zalznxpzztokxrdee	30	9	tion	tion	NN
work_kwvyudrv4zalznxpzztokxrdee	30	10	in	in	IN
work_kwvyudrv4zalznxpzztokxrdee	30	11	2000	2000	CD
work_kwvyudrv4zalznxpzztokxrdee	30	12	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	30	13	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	30	14	we	-PRON-	PRP
work_kwvyudrv4zalznxpzztokxrdee	30	15	examined	examine	VBD
work_kwvyudrv4zalznxpzztokxrdee	30	16	pharmacy	pharmacy	NN
work_kwvyudrv4zalznxpzztokxrdee	30	17	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	30	18	hospital	hospital	NN
work_kwvyudrv4zalznxpzztokxrdee	30	19	use	use	NN
work_kwvyudrv4zalznxpzztokxrdee	30	20	/	/	SYM
work_kwvyudrv4zalznxpzztokxrdee	30	21	costs	cost	NNS
work_kwvyudrv4zalznxpzztokxrdee	30	22	in	in	IN
work_kwvyudrv4zalznxpzztokxrdee	30	23	2001	2001	CD
work_kwvyudrv4zalznxpzztokxrdee	30	24	.	.	.
work_kwvyudrv4zalznxpzztokxrdee	31	1	Descriptive	descriptive	JJ
work_kwvyudrv4zalznxpzztokxrdee	31	2	analyses	analysis	NNS
work_kwvyudrv4zalznxpzztokxrdee	31	3	compared	compare	VBN
work_kwvyudrv4zalznxpzztokxrdee	31	4	mean	mean	VBP
work_kwvyudrv4zalznxpzztokxrdee	31	5	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	31	6	total	total	JJ
work_kwvyudrv4zalznxpzztokxrdee	31	7	costs	cost	NNS
work_kwvyudrv4zalznxpzztokxrdee	31	8	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	31	9	as	as	RB
work_kwvyudrv4zalznxpzztokxrdee	31	10	well	well	RB
work_kwvyudrv4zalznxpzztokxrdee	31	11	as	as	IN
work_kwvyudrv4zalznxpzztokxrdee	31	12	proportions	proportion	NNS
work_kwvyudrv4zalznxpzztokxrdee	31	13	within	within	IN
work_kwvyudrv4zalznxpzztokxrdee	31	14	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	31	15	population	population	NN
work_kwvyudrv4zalznxpzztokxrdee	31	16	.	.	.
work_kwvyudrv4zalznxpzztokxrdee	32	1	RESULTS	RESULTS	NNP
work_kwvyudrv4zalznxpzztokxrdee	32	2	:	:	:
work_kwvyudrv4zalznxpzztokxrdee	32	3	We	-PRON-	PRP
work_kwvyudrv4zalznxpzztokxrdee	32	4	iden-	iden-	VBP
work_kwvyudrv4zalznxpzztokxrdee	32	5	tified	tifie	VBD
work_kwvyudrv4zalznxpzztokxrdee	32	6	five	five	CD
work_kwvyudrv4zalznxpzztokxrdee	32	7	highly	highly	RB
work_kwvyudrv4zalznxpzztokxrdee	32	8	prevalent	prevalent	JJ
work_kwvyudrv4zalznxpzztokxrdee	32	9	chronic	chronic	JJ
work_kwvyudrv4zalznxpzztokxrdee	32	10	conditions	condition	NNS
work_kwvyudrv4zalznxpzztokxrdee	32	11	:	:	:
work_kwvyudrv4zalznxpzztokxrdee	32	12	cardiovascular	cardiovascular	JJ
work_kwvyudrv4zalznxpzztokxrdee	32	13	dis-	dis-	IN
work_kwvyudrv4zalznxpzztokxrdee	32	14	eases	ease	NNS
work_kwvyudrv4zalznxpzztokxrdee	32	15	(	(	-LRB-
work_kwvyudrv4zalznxpzztokxrdee	32	16	N	n	NN
work_kwvyudrv4zalznxpzztokxrdee	32	17	=	=	SYM
work_kwvyudrv4zalznxpzztokxrdee	32	18	824,190	824,190	CD
work_kwvyudrv4zalznxpzztokxrdee	32	19	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	32	20	20.8	20.8	CD
work_kwvyudrv4zalznxpzztokxrdee	32	21	%	%	NN
work_kwvyudrv4zalznxpzztokxrdee	32	22	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	32	23	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	32	24	population	population	NN
work_kwvyudrv4zalznxpzztokxrdee	32	25	)	)	-RRB-
work_kwvyudrv4zalznxpzztokxrdee	32	26	;	;	:
work_kwvyudrv4zalznxpzztokxrdee	32	27	rheumatologic	rheumatologic	NN
work_kwvyudrv4zalznxpzztokxrdee	32	28	conditions	condition	NNS
work_kwvyudrv4zalznxpzztokxrdee	32	29	(	(	-LRB-
work_kwvyudrv4zalznxpzztokxrdee	32	30	N	n	CD
work_kwvyudrv4zalznxpzztokxrdee	32	31	=	=	SYM
work_kwvyudrv4zalznxpzztokxrdee	32	32	172,402	172,402	CD
work_kwvyudrv4zalznxpzztokxrdee	32	33	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	32	34	4.4	4.4	CD
work_kwvyudrv4zalznxpzztokxrdee	32	35	%	%	NN
work_kwvyudrv4zalznxpzztokxrdee	32	36	)	)	-RRB-
work_kwvyudrv4zalznxpzztokxrdee	32	37	;	;	:
work_kwvyudrv4zalznxpzztokxrdee	32	38	gastric	gastric	JJ
work_kwvyudrv4zalznxpzztokxrdee	32	39	acid	acid	NN
work_kwvyudrv4zalznxpzztokxrdee	32	40	disorders	disorder	NNS
work_kwvyudrv4zalznxpzztokxrdee	32	41	(	(	-LRB-
work_kwvyudrv4zalznxpzztokxrdee	32	42	N	n	NN
work_kwvyudrv4zalznxpzztokxrdee	32	43	=	=	SYM
work_kwvyudrv4zalznxpzztokxrdee	32	44	142,191	142,191	CD
work_kwvyudrv4zalznxpzztokxrdee	32	45	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	32	46	3.6	3.6	CD
work_kwvyudrv4zalznxpzztokxrdee	32	47	%	%	NN
work_kwvyudrv4zalznxpzztokxrdee	32	48	)	)	-RRB-
work_kwvyudrv4zalznxpzztokxrdee	32	49	;	;	,
work_kwvyudrv4zalznxpzztokxrdee	32	50	chronic	chronic	JJ
work_kwvyudrv4zalznxpzztokxrdee	32	51	respiratory	respiratory	JJ
work_kwvyudrv4zalznxpzztokxrdee	32	52	illnesses	illness	NNS
work_kwvyudrv4zalznxpzztokxrdee	32	53	(	(	-LRB-
work_kwvyudrv4zalznxpzztokxrdee	32	54	N	n	NN
work_kwvyudrv4zalznxpzztokxrdee	32	55	=	=	SYM
work_kwvyudrv4zalznxpzztokxrdee	32	56	154,601	154,601	CD
work_kwvyudrv4zalznxpzztokxrdee	32	57	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	32	58	3.9	3.9	CD
work_kwvyudrv4zalznxpzztokxrdee	32	59	%	%	NN
work_kwvyudrv4zalznxpzztokxrdee	32	60	)	)	-RRB-
work_kwvyudrv4zalznxpzztokxrdee	32	61	;	;	:
work_kwvyudrv4zalznxpzztokxrdee	32	62	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	32	63	psychiatric	psychiatric	JJ
work_kwvyudrv4zalznxpzztokxrdee	32	64	disorders	disorder	NNS
work_kwvyudrv4zalznxpzztokxrdee	32	65	(	(	-LRB-
work_kwvyudrv4zalznxpzztokxrdee	32	66	94,140	94,140	CD
work_kwvyudrv4zalznxpzztokxrdee	32	67	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	32	68	2.4	2.4	CD
work_kwvyudrv4zalznxpzztokxrdee	32	69	%	%	NN
work_kwvyudrv4zalznxpzztokxrdee	32	70	)	)	-RRB-
work_kwvyudrv4zalznxpzztokxrdee	32	71	.	.	.
work_kwvyudrv4zalznxpzztokxrdee	33	1	27.3	27.3	CD
work_kwvyudrv4zalznxpzztokxrdee	33	2	%	%	NN
work_kwvyudrv4zalznxpzztokxrdee	33	3	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	33	4	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	33	5	population	population	NN
work_kwvyudrv4zalznxpzztokxrdee	33	6	had	have	VBD
work_kwvyudrv4zalznxpzztokxrdee	33	7	one	one	CD
work_kwvyudrv4zalznxpzztokxrdee	33	8	or	or	CC
work_kwvyudrv4zalznxpzztokxrdee	33	9	more	more	JJR
work_kwvyudrv4zalznxpzztokxrdee	33	10	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	33	11	these	these	DT
work_kwvyudrv4zalznxpzztokxrdee	33	12	five	five	CD
work_kwvyudrv4zalznxpzztokxrdee	33	13	chronic	chronic	JJ
work_kwvyudrv4zalznxpzztokxrdee	33	14	conditions	condition	NNS
work_kwvyudrv4zalznxpzztokxrdee	33	15	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	33	16	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	33	17	these	these	DT
work_kwvyudrv4zalznxpzztokxrdee	33	18	individuals	individual	NNS
work_kwvyudrv4zalznxpzztokxrdee	33	19	accounted	account	VBD
work_kwvyudrv4zalznxpzztokxrdee	33	20	for	for	IN
work_kwvyudrv4zalznxpzztokxrdee	33	21	72.8	72.8	CD
work_kwvyudrv4zalznxpzztokxrdee	33	22	%	%	NN
work_kwvyudrv4zalznxpzztokxrdee	33	23	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	33	24	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	33	25	pharmacy	pharmacy	NN
work_kwvyudrv4zalznxpzztokxrdee	33	26	costs	cost	NNS
work_kwvyudrv4zalznxpzztokxrdee	33	27	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	33	28	58.9	58.9	CD
work_kwvyudrv4zalznxpzztokxrdee	33	29	%	%	NN
work_kwvyudrv4zalznxpzztokxrdee	33	30	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	33	31	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	33	32	hospital	hospital	NN
work_kwvyudrv4zalznxpzztokxrdee	33	33	costs	cost	NNS
work_kwvyudrv4zalznxpzztokxrdee	33	34	in	in	IN
work_kwvyudrv4zalznxpzztokxrdee	33	35	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	33	36	following	following	JJ
work_kwvyudrv4zalznxpzztokxrdee	33	37	year	year	NN
work_kwvyudrv4zalznxpzztokxrdee	33	38	.	.	.
work_kwvyudrv4zalznxpzztokxrdee	34	1	For	for	IN
work_kwvyudrv4zalznxpzztokxrdee	34	2	persons	person	NNS
work_kwvyudrv4zalznxpzztokxrdee	34	3	with	with	IN
work_kwvyudrv4zalznxpzztokxrdee	34	4	these	these	DT
work_kwvyudrv4zalznxpzztokxrdee	34	5	five	five	CD
work_kwvyudrv4zalznxpzztokxrdee	34	6	conditions	condition	NNS
work_kwvyudrv4zalznxpzztokxrdee	34	7	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	34	8	we	-PRON-	PRP
work_kwvyudrv4zalznxpzztokxrdee	34	9	also	also	RB
work_kwvyudrv4zalznxpzztokxrdee	34	10	described	describe	VBD
work_kwvyudrv4zalznxpzztokxrdee	34	11	use	use	NN
work_kwvyudrv4zalznxpzztokxrdee	34	12	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	34	13	costs	cost	NNS
work_kwvyudrv4zalznxpzztokxrdee	34	14	by	by	IN
work_kwvyudrv4zalznxpzztokxrdee	34	15	age	age	NN
work_kwvyudrv4zalznxpzztokxrdee	34	16	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	34	17	gender	gender	NN
work_kwvyudrv4zalznxpzztokxrdee	34	18	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	34	19	residence	residence	NN
work_kwvyudrv4zalznxpzztokxrdee	34	20	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	34	21	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	34	22	income	income	NN
work_kwvyudrv4zalznxpzztokxrdee	34	23	.	.	.
work_kwvyudrv4zalznxpzztokxrdee	35	1	CONCLUSIONS	conclusion	NNS
work_kwvyudrv4zalznxpzztokxrdee	35	2	:	:	:
work_kwvyudrv4zalznxpzztokxrdee	35	3	Interest-	interest-	IN
work_kwvyudrv4zalznxpzztokxrdee	35	4	ingly	ingly	RB
work_kwvyudrv4zalznxpzztokxrdee	35	5	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	35	6	one	one	CD
work_kwvyudrv4zalznxpzztokxrdee	35	7	-	-	HYPH
work_kwvyudrv4zalznxpzztokxrdee	35	8	fourth	fourth	NN
work_kwvyudrv4zalznxpzztokxrdee	35	9	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	35	10	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	35	11	population	population	NN
work_kwvyudrv4zalznxpzztokxrdee	35	12	with	with	IN
work_kwvyudrv4zalznxpzztokxrdee	35	13	selected	select	VBN
work_kwvyudrv4zalznxpzztokxrdee	35	14	chronic	chronic	JJ
work_kwvyudrv4zalznxpzztokxrdee	35	15	condi-	condi-	NNP
work_kwvyudrv4zalznxpzztokxrdee	35	16	tions	tion	NNS
work_kwvyudrv4zalznxpzztokxrdee	35	17	accounted	account	VBD
work_kwvyudrv4zalznxpzztokxrdee	35	18	for	for	IN
work_kwvyudrv4zalznxpzztokxrdee	35	19	large	large	JJ
work_kwvyudrv4zalznxpzztokxrdee	35	20	proportions	proportion	NNS
work_kwvyudrv4zalznxpzztokxrdee	35	21	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	35	22	cost	cost	NN
work_kwvyudrv4zalznxpzztokxrdee	35	23	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	35	24	use	use	NN
work_kwvyudrv4zalznxpzztokxrdee	35	25	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	35	26	health	health	NN
work_kwvyudrv4zalznxpzztokxrdee	35	27	services	service	NNS
work_kwvyudrv4zalznxpzztokxrdee	35	28	.	.	.
work_kwvyudrv4zalznxpzztokxrdee	36	1	The	the	DT
work_kwvyudrv4zalznxpzztokxrdee	36	2	ability	ability	NN
work_kwvyudrv4zalznxpzztokxrdee	36	3	to	to	TO
work_kwvyudrv4zalznxpzztokxrdee	36	4	identify	identify	VB
work_kwvyudrv4zalznxpzztokxrdee	36	5	those	those	DT
work_kwvyudrv4zalznxpzztokxrdee	36	6	with	with	IN
work_kwvyudrv4zalznxpzztokxrdee	36	7	chronic	chronic	JJ
work_kwvyudrv4zalznxpzztokxrdee	36	8	conditions	condition	NNS
work_kwvyudrv4zalznxpzztokxrdee	36	9	would	would	MD
work_kwvyudrv4zalznxpzztokxrdee	36	10	help	help	VB
work_kwvyudrv4zalznxpzztokxrdee	36	11	planners	planner	NNS
work_kwvyudrv4zalznxpzztokxrdee	36	12	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	36	13	governmental	governmental	JJ
work_kwvyudrv4zalznxpzztokxrdee	36	14	agencies	agency	NNS
work_kwvyudrv4zalznxpzztokxrdee	36	15	to	to	TO
work_kwvyudrv4zalznxpzztokxrdee	36	16	address	address	VB
work_kwvyudrv4zalznxpzztokxrdee	36	17	health	health	NN
work_kwvyudrv4zalznxpzztokxrdee	36	18	care	care	NN
work_kwvyudrv4zalznxpzztokxrdee	36	19	needs	need	NNS
work_kwvyudrv4zalznxpzztokxrdee	36	20	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	36	21	increase	increase	VB
work_kwvyudrv4zalznxpzztokxrdee	36	22	quality	quality	NN
work_kwvyudrv4zalznxpzztokxrdee	36	23	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	36	24	care	care	NN
work_kwvyudrv4zalznxpzztokxrdee	36	25	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	36	26	avoid	avoid	VB
work_kwvyudrv4zalznxpzztokxrdee	36	27	unnecessary	unnecessary	JJ
work_kwvyudrv4zalznxpzztokxrdee	36	28	hospitalizations	hospitalization	NNS
work_kwvyudrv4zalznxpzztokxrdee	36	29	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	36	30	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	36	31	save	save	VB
work_kwvyudrv4zalznxpzztokxrdee	36	32	costs	cost	NNS
work_kwvyudrv4zalznxpzztokxrdee	36	33	.	.	.
work_kwvyudrv4zalznxpzztokxrdee	37	1	These	these	DT
work_kwvyudrv4zalznxpzztokxrdee	37	2	types	type	NNS
work_kwvyudrv4zalznxpzztokxrdee	37	3	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	37	4	data	datum	NNS
work_kwvyudrv4zalznxpzztokxrdee	37	5	can	can	MD
work_kwvyudrv4zalznxpzztokxrdee	37	6	be	be	VB
work_kwvyudrv4zalznxpzztokxrdee	37	7	used	use	VBN
work_kwvyudrv4zalznxpzztokxrdee	37	8	to	to	TO
work_kwvyudrv4zalznxpzztokxrdee	37	9	estimate	estimate	VB
work_kwvyudrv4zalznxpzztokxrdee	37	10	health	health	NN
work_kwvyudrv4zalznxpzztokxrdee	37	11	care	care	NN
work_kwvyudrv4zalznxpzztokxrdee	37	12	financing	financing	NN
work_kwvyudrv4zalznxpzztokxrdee	37	13	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	37	14	risk	risk	NN
work_kwvyudrv4zalznxpzztokxrdee	37	15	adjustment	adjustment	NN
work_kwvyudrv4zalznxpzztokxrdee	37	16	models	model	NNS
work_kwvyudrv4zalznxpzztokxrdee	37	17	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	37	18	and	and	CC
work_kwvyudrv4zalznxpzztokxrdee	37	19	profile	profile	VB
work_kwvyudrv4zalznxpzztokxrdee	37	20	specific	specific	JJ
work_kwvyudrv4zalznxpzztokxrdee	37	21	clinical	clinical	JJ
work_kwvyudrv4zalznxpzztokxrdee	37	22	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	37	23	demographic	demographic	JJ
work_kwvyudrv4zalznxpzztokxrdee	37	24	or	or	CC
work_kwvyudrv4zalznxpzztokxrdee	37	25	geographic	geographic	JJ
work_kwvyudrv4zalznxpzztokxrdee	37	26	sub	sub	NN
work_kwvyudrv4zalznxpzztokxrdee	37	27	-	-	NNS
work_kwvyudrv4zalznxpzztokxrdee	37	28	groups	group	NNS
work_kwvyudrv4zalznxpzztokxrdee	37	29	.	.	.
work_kwvyudrv4zalznxpzztokxrdee	38	1	PHP26	PHP26	NNP
work_kwvyudrv4zalznxpzztokxrdee	38	2	ADHERENCE	ADHERENCE	NNP
work_kwvyudrv4zalznxpzztokxrdee	38	3	INDEX	INDEX	NNP
work_kwvyudrv4zalznxpzztokxrdee	38	4	OF	of	IN
work_kwvyudrv4zalznxpzztokxrdee	38	5	PERFORMANCE	performance	NN
work_kwvyudrv4zalznxpzztokxrdee	38	6	—	—	:
work_kwvyudrv4zalznxpzztokxrdee	38	7	A	a	DT
work_kwvyudrv4zalznxpzztokxrdee	38	8	NEW	new	JJ
work_kwvyudrv4zalznxpzztokxrdee	38	9	METHOD	method	NN
work_kwvyudrv4zalznxpzztokxrdee	38	10	AND	and	CC
work_kwvyudrv4zalznxpzztokxrdee	38	11	TOOL	tool	NN
work_kwvyudrv4zalznxpzztokxrdee	38	12	FOR	for	IN
work_kwvyudrv4zalznxpzztokxrdee	38	13	ONGOING	ONGOING	NNP
work_kwvyudrv4zalznxpzztokxrdee	38	14	EVALUATION	EVALUATION	NNPS
work_kwvyudrv4zalznxpzztokxrdee	38	15	OF	of	IN
work_kwvyudrv4zalznxpzztokxrdee	38	16	MEDICATION	medication	NN
work_kwvyudrv4zalznxpzztokxrdee	38	17	ADHERENCE	ADHERENCE	NNP
work_kwvyudrv4zalznxpzztokxrdee	38	18	IMPROVEMENT	improvement	NN
work_kwvyudrv4zalznxpzztokxrdee	38	19	INITIATIVES	initiatives	NN
work_kwvyudrv4zalznxpzztokxrdee	38	20	Day	Day	NNP
work_kwvyudrv4zalznxpzztokxrdee	38	21	D	D	NNP
work_kwvyudrv4zalznxpzztokxrdee	38	22	Pfizer	Pfizer	NNP
work_kwvyudrv4zalznxpzztokxrdee	38	23	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	38	24	New	New	NNP
work_kwvyudrv4zalznxpzztokxrdee	38	25	York	York	NNP
work_kwvyudrv4zalznxpzztokxrdee	38	26	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	38	27	NY	NY	NNP
work_kwvyudrv4zalznxpzztokxrdee	38	28	,	,	,
work_kwvyudrv4zalznxpzztokxrdee	38	29	USA	USA	NNP
work_kwvyudrv4zalznxpzztokxrdee	38	30	OBJECTIVES	OBJECTIVES	NNP
work_kwvyudrv4zalznxpzztokxrdee	38	31	:	:	:
work_kwvyudrv4zalznxpzztokxrdee	38	32	To	to	TO
work_kwvyudrv4zalznxpzztokxrdee	38	33	develop	develop	VB
work_kwvyudrv4zalznxpzztokxrdee	38	34	a	a	DT
work_kwvyudrv4zalznxpzztokxrdee	38	35	standardized	standardized	JJ
work_kwvyudrv4zalznxpzztokxrdee	38	36	means	mean	NNS
work_kwvyudrv4zalznxpzztokxrdee	38	37	for	for	IN
work_kwvyudrv4zalznxpzztokxrdee	38	38	measuring	measure	VBG
work_kwvyudrv4zalznxpzztokxrdee	38	39	the	the	DT
work_kwvyudrv4zalznxpzztokxrdee	38	40	impact	impact	NN
work_kwvyudrv4zalznxpzztokxrdee	38	41	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	38	42	medication	medication	NN
work_kwvyudrv4zalznxpzztokxrdee	38	43	adherence	adherence	NN
work_kwvyudrv4zalznxpzztokxrdee	38	44	improvement	improvement	NN
work_kwvyudrv4zalznxpzztokxrdee	38	45	initiatives	initiative	NNS
work_kwvyudrv4zalznxpzztokxrdee	38	46	in	in	IN
work_kwvyudrv4zalznxpzztokxrdee	38	47	disparate	disparate	JJ
work_kwvyudrv4zalznxpzztokxrdee	38	48	pharmacy	pharmacy	NN
work_kwvyudrv4zalznxpzztokxrdee	38	49	claims	claim	NNS
work_kwvyudrv4zalznxpzztokxrdee	38	50	databases	database	NNS
work_kwvyudrv4zalznxpzztokxrdee	38	51	over	over	RB
work_kwvyudrv4zalznxpzztokxrdee	38	52	sequentially	sequentially	RB
work_kwvyudrv4zalznxpzztokxrdee	38	53	overlap-	overlap-	NN
work_kwvyudrv4zalznxpzztokxrdee	38	54	ping	ping	NN
work_kwvyudrv4zalznxpzztokxrdee	38	55	periods	period	NNS
work_kwvyudrv4zalznxpzztokxrdee	38	56	of	of	IN
work_kwvyudrv4zalznxpzztokxrdee	38	57	time	time	NN
work_kwvyudrv4zalznxpzztokxrdee	38	58	.	.	.
work_kwvyudrv4zalznxpzztokxrdee	39	1	METHODS	methods	JJ
work_kwvyudrv4zalznxpzztokxrdee	39	2	:	:	:
work_kwvyudrv4zalznxpzztokxrdee	39	3	The	the	DT
work_kwvyudrv4zalznxpzztokxrdee	39	4	Adherence	Adherence	NNP
work_kwvyudrv4zalznxpzztokxrdee	39	5	Index	Index	NNP
work_kwvyudrv4zalznxpzztokxrdee	39	6	of	of	IN